Changes in hepatic immunoregulatory cytokines in patients with metastatic colorectal carcinoma: Implications for hepatic anti-tumour immunity

Cytokine

Volumn 35, Issue 3-4, 2006, Pages 171-179

  Kelly, Anna M ^a   Golden Mason, Lucy ^a   Traynor, Oscar ^a   Geoghegan, Justin ^a   McEntee, Gerry ^a   Hegarty, John E ^a,b   O'Farrelly, Cliona ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cytokines; Human; Microenvironment; Normal liver; Tumour immunity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INFLAMMATION; LIVER; LIVER TUMOR; METASTASIS; PLANT PARENCHYMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR IMMUNITY;

COLORECTAL NEOPLASMS; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; INTERFERON TYPE II; INTERLEUKIN-10; LIVER; LIVER NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM;

EID: 33750519061     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.07.019     Document Type: Article

References (41)

1. Doherty D.G., and O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 174 (2000) 5-20
2. Taylor I. Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br J Surg 83 4 (1996) 456-460
3. Memon M.A., and Beckingham I.J. Surgical resection of colorectal liver metastases. Colorectal Dis 3 6 (2001) 361-373
4. Adam R., Huguet E., Azoulay D., Castaing D., Kunstlinger F., Levi F., et al. Hepatic resection after down-staging of unresectable hepatic colorectal metastases. Surg Oncol Clin N Am 12 1 (2003) 211-220 xii
5. Dunne J., Lynch S., O'Farrelly C., Todryk S., Hegarty J.E., Feighery C., et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 167 6 (2001) 3129-3138
6. Satoh M., Seki S., Hashimoto W., Ogasawara K., Kobayashi T., Kumagai K., et al. J Immunol 157 9 (1996) 3886-3892
7. Dao T., Mehal W.Z., and Crispe I.N. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J Immunol 161 5 (1998) 2217-2222
8. Doherty D.G., Norris S., Madrigal-Estebas L., McEntee G., Traynor O., Hegarty J.E., et al. J Immunol 163 4 (1999) 2314-2321
9. Bertoletti A., D'Elios M.M., Boni C., De Carli M., Zignego A.L., Durazzo M., et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 112 1 (1997) 193-199
10. Hashimoto W., Takeda K., Anzai R., Ogasawara K., Sakihara H., Sugiura K., et al. J Immunol 154 9 (1995) 4333-4340
11. Takeda K., Seki S., Ogasawara K., Anzai R., Hashimoto W., Sugiura K., et al. J Immunol 156 9 (1996) 3366-3373
12. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
13. Nabioullin R., Sone S., Mizuno K., Yano S., Nishioka Y., Haku T., et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol 55 4 (1994) 437-442
14. Holland G., and Zlotnik A. Interleukin-10 and cancer. Cancer Invest 11 6 (1993) 751-758
15. Matsuda M., Salazar F., Petersson M., Masucci G., Hansson J., Pisa P., et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180 6 (1994) 2371-2376
16. Chau G.Y., Wu C.W., Lui W.Y., Chang T.J., Kao H.L., Wu L.H., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231 4 (2000) 552-558
17. Fortis C., Foppoli M., Gianotti L., Galli L., Citterio G., Consogno G., et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 104 1 (1996) 1-5
18. Blay J.Y., Burdin N., Rousset F., Lenoir G., Biron P., Philip T., et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82 7 (1993) 2169-2174
19. Ordemann J., Jacobi C.A., Braumann C., Schwenk W., Volk H.D., Muller J.M., and Immunomodulatory changes in patients with colorectal c. Int J Colorectal Dis 17 1 (2002) 37-41
20. Galizia G., Orditura M., Romano C., Lieto E., Castellano P., Pelosio L., et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102 2 (2002) 169-178
21. Hattori E., Okumoto K., Adachi T., Takeda T., Ito J., Sugahara K., et al. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol Res 27 4 (2003) 309-314
22. Figlin R.A. Renal cell carcinoma: current status and future plans. Cancer J Sci Am 6 Suppl1 (2000) S52-S54
23. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 7 (1999) 2105-2116
24. Carson W.E., Giri J.G., Lindemann M.J., Linett M.L., Ahdieh M., Paxton R., et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180 4 (1994) 1395-1403
25. Kohyama M., Saijyo K., Hayasida M., Yasugi T., Kurimoto M., and Ohno T. Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Jpn J Cancer Res 89 10 (1998) 1041-1046
26. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 6 (2000) 515-520
27. Kelly A.M., Golden-Mason L., McEntee G., Traynor O., Doherty D.G., Hegarty J.E., et al. Interleukin 12 (IL-12) is increased in tumour bearing human liver and expands CD8(+) and CD56(+) T cells in vitro but not in vivo. Cytokine 25 6 (2004) 273-282
28. Smith K.A. Interleukin-2: inception, impact, and implications. Science 240 4856 (1988) 1169-1176
29. Ogasawara K., Hida S., Azimi N., Tagaya Y., Sato T., Yokochi-Fukuda T., et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391 6668 (1998) 700-703
30. Ohteki T., Ho S., Suzuki H., Mak T.W., and Ohashi P.S. Role for IL-15/IL-15 receptor beta-chain in natural killer 1.1+ T cell receptor-alpha beta+ cell development. J Immunol 159 12 (1997) 5931-5935
31. Tsutsui H., Nakanishi K., Matsui K., Higashino K., Okamura H., Miyazawa Y., et al. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157 9 (1996) 3967-3973
32. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 342 18 (2000) 1350-1358
33. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 151 11 (1993) 6370-6381
34. McKenzie G.J., Fallon P.G., Emson C.L., Grencis R.K., and McKenzie A.N. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 189 10 (1999) 1565-1572
35. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., and McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24 4 (1996) 759-765
36. McGuinness P.H., Painter D., Davies S., and McCaughan G.W. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46 2 (2000) 260-269
37. Golden-Mason L., Kelly A.M., Traynor O., McEntee G., Kelly J., Hegarty J.E., et al. Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development. Cytokine 14 3 (2001) 143-151
38. Waldmann T.A., and Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17 (1999) 19-49
39. Bortolami M., Venturi C., Giacomelli L., Scalerta R., Bacchetti S., Marino F., et al. Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis 34 11 (2002) 794-801
40. de Waal Malefyt R., Yssel H., and de Vries J.E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150 11 (1993) 4754-4765
41. Taga K., and Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148 4 (1992) 1143-1148